Acylated glucagon analogues

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9896495
SERIAL NO

14517497

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ZEALAND PHARMA A/SSMEDELAND 36 GLOSTRUP DK-2600

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Hamprecht, Dieter Wolfgang Pozzolengo, IT 32 310
Riber, Ditte Brønshøj, DK 48 1015
Rist, Wolfgang Ingelheim Am Rhein, DE 14 131
Tolborg, Jakob Lind Herlev, DK 22 424

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Aug 20, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Aug 20, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00